



COVID-19 agent molnupiravir

Molnupiravir (Lagevrio®) is an antiviral medication to treat mild to medium COVID-19 infection. Molnupiravir is actually a prodrug of the active substrate *N*⁴-hydroxycytidine (NHC), a synthetic ribonucleoside analogue. The treatment leads to the introduction of copying errors during viral RNA replication and by this inhibits the viral reproduction.

Molnupiravir and its active agent β -d-*N*⁴-hydroxycytidine can be separated by using a YMC-Triart C18 column and a MS compatible mobile phase at pH4.3 and relatively mild temperatures of 40°C.



